April 22nd 2024
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Considerations for Choosing Between Newer Agents in R/R B-Cell ALL
September 9th 2020In the past 5 years, 3 new treatment options have emerged to treat patients with relapsed or refractory acute lymphoblastic leukemia, providing hope for patients with this disease, but also raising clinical questions of how to choose among these agents and what is the best option for the patient at which time.
Read More
CC-486 Constitutes Standard of Care for Subset of Patients with AML
September 5th 2020In an interview with Targeted Oncology Guillermo Garcia-Manero, MD, discussed the key findings from the QUAZAR AML-001 study and the importance of the FDA approval of CC-486 in post-remission acute myeloid leukemia.
Read More
FDA Approves CC-486 as Maintenance Therapy in Acute Myeloid Leukemia
September 1st 2020The FDA granted approval to the oral hypomethylating agent, CC-486 (azacitidine tablets, Onureg), as a maintenance treatment for adult patients with acute myeloid leukemia who achieved a first complete remission or with incomplete blood count recovery after intensive induction chemotherapy and who are unable to complete intensive curative therapy.
Read More
Novel STAMP Inhibitor Asciminib Meets Primary End Point in Phase 3 Study of Chronic Myeloid Leukemia
August 26th 2020The primary end point of statistically superiority in major molecular response rate at 24 weeks was met with asciminib versus bosutinib as treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the phase 3 ASCEMBL study.
Read More
Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients
July 31st 2020Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.
Watch
Hyper-CVAD Plus Ofatumumab Demonstrates Activity in Ph-Negative, CD20-Positive B-Cell ALL
July 15th 2020“In this single-arm, phase 2 study, the combination of ofatumumab with the hyper-CVAD regimen resulted in a high proportion of adult patients with Ph-negative CD20- positive B-cell acute lymphoblastic leukemia having durable remission and long-term survival…"
Read More
Phase 3 Study Confirms Benefit of Venetoclax/LDAC in Chemotherapy-Ineligible AML
July 3rd 2020A new randomized placebo-controlled study finds patients with acute myeloid leukemia who cannot undergo intensive chemotherapy have improved outcomes when given venetoclax in addition to low-dose cytarabine.
Read More
Discontinuation of Venetoclax Impacts Outcomes of Rituximab Combination in CLL
June 25th 2020In an interview with Targeted Oncology, Anthony Mato, MD, discussed the findings of venetoclax interruptions or discontinuations observed in patients with relapsed/refractory chronic lymphocytic leukemia who received the combination of venetoclax plus rituximab in the phase 3 MURANO study.
Read More
Complex Karyotype Strongly Associated With Shorter PFS in Chronic Lymphocytic Leukemia
June 25th 2020All patients with relapsed/refractory chronic lymphocytic leukemia should be evaluated for both complex karyotypes and del17p prior to initiating treatment, and all patients with complex karyotypes should be considered candidates for alternative combination therapy.
Read More
Managing Patients With Myeloid Malignancies During and After the Global COVID-19 Pandemic
June 24th 2020During the Virtual 25th Congress of the European Hematology Association (EHA), a group of physicians described their experiences and recommendations for managing patients with myeloid malignancies during the COVID-19 pandemic and after.
Read More
Disparities Seen in Hematologic Cancer Incidence and Survival for Hispanic Patients in Texas
June 22nd 2020“[This] report on the diagnosis of blood cancers in the US/Mexico border inure the different frequency of leukemia subtypes and their outcomes, highlighting important health disparities due to different access to diagnosis and care due to a series of factors."
Read More
Ublituximab Plus Ibrutinib Induces Promises Responses in High-Risk Relapsed/Refractory CLL
June 11th 2020In an interview with Targeted Oncology, Jeff P. Sharman, MD, discussed the findings for the combination of ublituximab plus ibrutinib as treatment of patients with high-risk relapsed/refractory chronic lymphocytic leukemia.
Read More
Microfluidic Platforms Help Isolate Rare Cells in Leukemias
May 17th 2020In an interview with Targeted Oncology, Steve A. Soper, PhD, discussed microfluidic platforms for use in isolating circulating leukemia cells and plasma cells in patients with acute lymphoblastic leukemia and acute myeloid leukemia.
Read More
Longest Follow-Up Maintains Ibrutinib Benefit in CLL/SLL Across Treatment Settings
April 13th 2020The longest follow-up for ibrutinib monotherapy to date maintained the benefit of the Bruton’s tyrosine kinase inhibitor for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma across settings.<br />
Read More
Prognostic Tool Predicts Length of Watch and Wait Period in CLL
April 10th 2020The appropriate gap between diagnosis of chronic lymphocytic leukemia and treatment is now clearer as a new prognostic tool, IPS-E, that can predict the length of “watch and wait” has been introduced, according to a press release from the American Society of Hematology.
Read More
Evaluating Older Patients With Acute Myeloid Leukemia in SIERRA Trial
April 8th 2020Rajneesh Nath, MD, discusses the rationale for phase III SIERRA trial, which evaluated the anti-CD45 monoclonal antibody apamistamab followed by fludarabine/total body irradiation and allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia.
Watch
Early FCR Lacks Evidence to Change Standard Watch & Wait in Stage Binet A High-Risk CLL
April 2nd 2020Although fludarabine, cyclophosphamide, and rituximab may be efficient in inducing remission for the treatment of patients with Binet A high-risk chronic lymphocytic leukemia, recent data published in Leukemia suggest there is no evidence that this would be better than the current standard of care, which is the “watch and wait” approach.
Read More
Acalabrutinib Appears Tolerable in Chronic Lymphocytic Leukemia
April 2nd 2020Jeff P. Sharman, MD, discusses the secondary end points from the <u><strong><a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib">phase III ELEVATE-TN trial</a></strong></u>, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Watch
AML Trial Halted Due to COVID-19 Pandemic
March 30th 2020A phase II trial of ficlatuzumab, an investigational HGF inhibitory antibody, in patients with relapsed and refractory acute myeloid leukemia joins the growing list of clinical trials halted due to the coronavirus disease 2019 pandemic.
Read More
Venetoclax Combination Improves OS in Acute Myeloid Leukemia
March 23rd 2020Venetoclax in combination with azacytidine demonstrated a statistically significant improvement in overall survival and achieved a satisfactory composite complete remission rate in previously untreated patients with acute myeloid leukemia, meeting the co-primary end points of the phase III VIALE-A study. Genentech, the developer of venetoclax, announced the positive news in a press release, also noting that safety profiles of both drugs were consistent with prior reports.
Read More
Positive Efficacy Achieved With Bendamustine Debulking Followed by Ofatumumab /Ibrutinib in CLL
March 19th 2020Bendamustine debulking followed by ofatumumab and ibrutinib demonstrated an overall response rate of 92% in patients with chronic lymphocytic leukemia, meeting the primary end point of the phase II CLL2-BIO trial, and was well-tolerated with no new safety signals. Results from the study were published in Haematologica.
Read More
86% Remission Rate Observed in Chemotherapy and ARC Combination in Relapsed/Refractory AML
March 11th 2020After demonstrating promising results that were comparable to targeted therapies in the first 2 cohorts of a phase I clinical trial, the combination of cladribine, cytarabine, granulocyte-colony stimulating factor, and mitoxantrone plus the antibody radiation conjugate lintuzumab-Ac225 in patients with relapsed/refractory acute myeloid leukemia is now being explored in a third cohort.
Read More
The Role of BTK Inhibitors Evolve for the Treatment of Patients With CLL
March 5th 2020In an interview with Targeted Oncology, Alexey V. Danilov, MD, PhD, discussed the ELEVATE-TN trial and other potentially practice-changing BTK inhibitor combinations expected to emerge in chronic lymphocytic leukemia.
Read More